Physician profile
Brian Yamada
NPI 1801849039
$3,882.35
in general payments reported to CMS, 2019-2025
15 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $496 · 2021: $526 · 2022: $840 · 2023: $562 · 2024: $489 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,629.69 | 2021-2025 | Interstim |
| Neotract INC. | $461.83 | 2019-2020 | |
| Teleflex LLC | $417.05 | 2021-2023 | Urolift |
| Medtronic USA, INC. | $309.07 | 2019-2020 | |
| Boston Scientific Corporation | $284.71 | 2020-2025 | Ams 800 Artificial Urinary Sphincter, Bulkamid |
| Axonics, INC. | $150.48 | 2022-2024 | Axonics |
| Urovant Sciences INC | $116.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $113.23 | 2019 | |
| Laborie Medical Technologies Corp. | $104.14 | 2025 | |
| Abbvie INC. | $100.05 | 2023-2025 | Botox |
| Coloplast Corp | $85.75 | 2020-2024 | Altis |
| Astellas Pharma US INC | $39.35 | 2019 | |
| Novo Nordisk INC | $31.07 | 2025 | Rivfloza |
| Teva Pharmaceuticals USA, INC. | $28.42 | 2025 | Uzedy |
| Endo Pharmaceuticals INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Yamada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.